Responses of DSIP in Sleep Pattern Regulation

 
Delta Sleep Inducing Peptide (DSIP) is a neuropeptide that appears to influence various endocrine and physiological functions in the nervous system. The peptide was isolated in 1977 from the brains of rats during slow-wave sleep.

DSIP may potentially lower oxidative stress and restore normal myocardial contractility. Furthermore, the peptide may potentially produce mitigatory action against depressive disorders and cancer cell proliferation. DSIP has also been researched for its potential to inhibit Somatostatin secretion, modify corticotropin levels, actions on blood pressure, stress hormone secretion and pain perception.

 

DSIP and Sleep Pattern Regulation

Some research suggests DSIP promotes slow-wave sleep while suppressing paradoxical sleep. It may also cause arousal in the first hour of sleep and sedation in the second. Research findings suggest that DSIP might normalize sleep and modulate sleep cycle dysfunctions. Sleep research involving DSIP was conducted in research models of chronic insomnia, and DSIP reportedly improved sleep to the same level as normal controls. This study supports previous findings that DSIP may reduce sleep latency and promotes sleep structure in chronic insomnia.^[4] The scientists note that “The [exposure] substantially improved night sleep with the first and additionally with repeated [introduction].”

According to the research, DSIP may potentially increase sleep time by 59% compared to a placebo, and delay sleep onset.^[5] These findings, however, contradict the EEG analysis of the research models under examining, which revealed no sedation. However, this may potentially be due to current testing patterns, as many EEG measures of sedation are based on pharmacologic sedation rather than natural sedation.

 

DSIP and Metabolism

DSIP research in rat models suggests that the peptide may limit stress-induced metabolic disturbances that cause the mitochondria to switch from oxygen-dependent to oxygen-independent respiration. The latter may produce dangerous metabolic byproducts. DSIP may be employed in research related to conditions such as heart attack and stroke due to its potential to maintain oxidative phosphorylation even in hypoxic conditions.^[8] DSIP may mitigate metabolic damage caused by oxygen deprivation by preserving normal mitochondrial function, thereby protecting tissues until blood flow is restored. DSIP may potentially reduce free radical production by maintaining normal mitochondrial functions.

DSIP research further suggests that the peptide may inhibit somatostatin secretion, contributing to skeletal muscle hypertrophy and hyperplasia.
According to Delta Sleep Inducing Peptide research, the peptide may influence blood pressure, thermogenesis, the lymphokine system, and heart rate.

 

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References

---

1. Popovich IG, Voitenkov BO, Anisimov VN, Ivanov VT, Mikhaleva II, Zabezhinski MA, Alimova IN, Baturin DA, Zavarzina NY, Rosenfeld SV, Semenchenko AV, Yashin AI. Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mech Ageing Dev. 2003 Jun;124(6):721-31. doi: 10.1016/s0047-6374(03)00082-4. PMID: 12782416.
2. A. B. Sinyukhin, G. P. Timoshinov, V. A. Kornilov, and P. D. Shabanov, “P.7.a.006 Delta sleep-inducing peptide analogue corrects the CNS functional state of children treated with antiblastomic therapy,” Eur. Neuropsychopharmacol., vol. 19, pp. S681–S682, Sep. 2009.
3. E. V. Koplik et al., “Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection,” Neurosci. Behav. Physiol., vol. 38, no. 9, pp. 953–957, Nov. 2008
4. Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987;27(2):120-9. doi: 10.1159/000116143. PMID: 3622582.
5. Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981 Aug;19(8):341-5. PMID: 6895513.
6. Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-85. doi: 10.1159/000115716. PMID: 6548970.
7. Nakamura A, Nakashima M, Sugao T, Kanemoto H, Fukumura Y, Shiomi H. Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP). Eur J Pharmacol. 1988 Oct 18;155(3):247-53. doi: 10.1016/0014-2999(88)90510-9. PMID: 2853064.
8. Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II. Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. Peptides. 2003 Feb;24(2):307-11. doi: 10.1016/s0196-9781(03)00040-8. PMID: 12668217.